Female Immunity Protects from Cutaneous Squamous Cell Carcinoma.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 06 2021
Historique:
received: 29 10 2020
revised: 08 02 2021
accepted: 25 03 2021
pubmed: 3 4 2021
medline: 22 3 2022
entrez: 2 4 2021
Statut: ppublish

Résumé

Cancer susceptibility and mortality are higher in males, and the mutational and transcriptomic landscape of cancer differs by sex. The current assumption is that men are at higher risk of epithelial cancers as they expose more to carcinogens and accumulate more damage than women. We present data showing women present with less aggressive primary cutaneous squamous cell carcinoma (cSCC) and early strong immune activation. We explored clinical and molecular sexual disparity in immunocompetent and immunosuppressed patients with primary cSCC ( We show cSCC is more aggressive in men, and immunocompetent women develop mild cSCC, later in life. To test whether sex drives disparity, we exposed male and female mice to equal doses of carcinogen, and found males present with more aggressive, metastatic cSCC than females. Critically, females activate cancer immune-related expression pathways and CD4 and CD8 T-cell infiltration independently of mutations, a response that is absent in prednisolone-treated animals. In contrast, males increase the rate of mitosis and proliferation in response to carcinogen. Women's skin and keratinocytes also activate immune-cancer fighting pathways and immune cells at UV radiation-damaged sites. Critically, a compromised immune system leads to high-risk, aggressive cSCC specifically in women. This work shows the immune response is sex biased in cSCC and highlights female immunity offers greater protection than male immunity.

Identifiants

pubmed: 33795258
pii: 1078-0432.CCR-20-4261
doi: 10.1158/1078-0432.CCR-20-4261
pmc: PMC7613610
mid: EMS154238
doi:

Substances chimiques

Carcinogens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3215-3223

Subventions

Organisme : Wellcome Trust
ID : 110078
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A27412
Pays : United Kingdom
Organisme : Wellcome
ID : 110078/Z/15/Z

Informations de copyright

©2021 American Association for Cancer Research.

Références

Hum Genet. 2020 Mar;139(3):333-356
pubmed: 31677133
Int J Cancer. 2001 Feb 1;91(3):402-6
pubmed: 11169966
Cancer Cell. 2016 May 9;29(5):711-722
pubmed: 27165743
Nature. 2001 Apr 26;410(6832):1107-11
pubmed: 11323675
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Nat Med. 2015 Aug;21(8):946-54
pubmed: 26168291
J Pathol. 2016 Oct;240(2):224-34
pubmed: 27447534
J Med Genet. 2014 Aug;51(8):545-52
pubmed: 24935963
N Engl J Med. 2015 Nov 12;373(20):1926-36
pubmed: 26559571
Cancer Res. 2007 Apr 1;67(7):3468-74
pubmed: 17389759
Nat Cancer. 2020 Aug;1(8):800-810
pubmed: 35122049
Food Chem Toxicol. 2016 Sep;95:149-58
pubmed: 27417450
J Am Acad Dermatol. 2013 Jun;68(6):957-66
pubmed: 23375456
PLoS One. 2018 Sep 13;13(9):e0203879
pubmed: 30212575
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
pubmed: 9636188
Br J Dermatol. 2021 Feb;184(2):328-337
pubmed: 32282938
Cancer. 2017 Jun 1;123(11):2054-2060
pubmed: 28171708
JAMA Dermatol. 2019 Mar 1;155(3):298-306
pubmed: 30484823
J Eur Acad Dermatol Venereol. 2019 Dec;33 Suppl 8:6-10
pubmed: 31833607
Nat Rev Cancer. 2014 Aug;14(8):547-58
pubmed: 25030953
Cancer Res. 2018 Oct 1;78(19):5527-5537
pubmed: 30275052
Nat Commun. 2020 Jun 1;11(1):2711
pubmed: 32483135
Cell. 2020 Jul 23;182(2):497-514.e22
pubmed: 32579974
JAMA Dermatol. 2013 May;149(5):541-7
pubmed: 23677079
Clin Cancer Res. 2011 Oct 1;17(19):6118-24
pubmed: 21705455
Nat Rev Cancer. 2007 Sep;7(9):645-58
pubmed: 17687385
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Nat Rev Cancer. 2016 May;16(5):330-9
pubmed: 27079803
Nat Commun. 2020 Mar 12;11(1):1335
pubmed: 32165639
Nat Genet. 2017 Jan;49(1):10-16
pubmed: 27869828
Nat Protoc. 2009;4(9):1350-62
pubmed: 19713956
Cancer Res. 2018 Oct 1;78(19):5538-5547
pubmed: 30275053
Nat Cell Biol. 2019 Jan;21(1):94-101
pubmed: 30602768

Auteurs

Timothy Budden (T)

Skin Cancer and Ageing Lab, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom.

Caroline Gaudy-Marqueste (C)

APHM, CRCM Inserm U1068, CNRS U7258, CHU Timone, Department of Dermatology and Skin Cancer, Aix-Marseille Univesrity, Marseille, France.

Sarah Craig (S)

Skin Cancer and Ageing Lab, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom.

Yuan Hu (Y)

Department of Otolaryngology, Head and Neck Surgery, University of Arizona, Tucson, Arizona.
University of Arizona Cancer Center, University of Arizona, Tucson, Arizona.
Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Charles H Earnshaw (CH)

Skin Cancer and Ageing Lab, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom.

Shilpa Gurung (S)

Skin Cancer and Ageing Lab, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom.

Amelle Ra (A)

Department of Dermatology, St. George's NHS Foundation Trust, London, United Kingdom.

Victoria Akhras (V)

Department of Dermatology, St. George's NHS Foundation Trust, London, United Kingdom.

Patrick Shenjere (P)

Department of Histopathology, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom.

Ruth Green (R)

Department of Histopathology, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom.

Lynne Jamieson (L)

Department of Histopathology, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom.

John Lear (J)

Department of Dermatology, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom.

Luisa Motta (L)

Department of Histopathology, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom.

Carlos Caulín (C)

Department of Otolaryngology, Head and Neck Surgery, University of Arizona, Tucson, Arizona.
University of Arizona Cancer Center, University of Arizona, Tucson, Arizona.

Deemesh Oudit (D)

Department of Plastic and Reconstructive Surgery, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom.

Simon J Furney (SJ)

Genomic Oncology Research Group, Department of Physiology and Medical Physics, Royal College of Surgeons, Dublin, Ireland.
Centre for Systems Medicine, Royal College of Surgeons, Dublin, Ireland.

Amaya Virós (A)

Skin Cancer and Ageing Lab, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom. amaya.viros@cruk.manchester.ac.uk.
NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom.
Department of Dermatology, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH